Table 2 Candidate compounds predicted to target prioritized PD-associated eGenes

Leupeptin

CTSB

Protease inhibitor

Tier 2

×

DNQX

ARSA

AMPA/kainate receptor antagonist

Tier 1

×

β-Solamarine

CTSB

Alkaloid, under research

Tier 2

×

4-Amino-1,8-naphthalimide

ARSA

Topoisomerase inhibitor

Tier 1

×

Gambierol

FAHD1

Potassium channel blocker

Tier 2

×

3,5-Dinitrocatechol

ARSA

COMT inhibitor (research)

Tier 1

×

Trifluridine

CTSB

Antiviral, anticancer

Tier 2

×

Amodiaquine

CTSB

Antimalarial

Tier 2

√

Mitoxantrone

ARSA;FDFT1

Anticancer, immunosuppressant

Tier 1

×

Tranilast

ARSA

Anti-allergic, antifibrotic

Tier 1

×

Seocalcitol

CTSB

Vitamin D analogue, anticancer

Tier 2

×

Alprazolam

CTSB

Anxiolytic

Tier 2

√

Tetrandrine

FDFT1

Calcium channel blocker, anti-inflammatory

Tier 1

×

1,2,9,10-Tetramethoxyaporphine

CTSB

Alkaloid (research)

Tier 2

×

Methadone hydrochloride

ARSA

Opioid analgesic

Tier 1

√

Felodipine

CTSB

Antihypertensive

Tier 2

√

Propylthiouracil

CTSB

Antithyroid

Tier 2

×

Remifentanil

ARSA

Opioid anesthetic

Tier 1

×

Salbutamol

CTSB

Beta-2 agonist (asthma)

Tier 2

×

Pravastatin

FDFT1

Cholesterol-lowering

Tier 1

×